SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy

Adam Brufsky, Yeon Hee Park, François-Clément Bidard, Erica L Mayer, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Hiroji Iwata, Peter A Fasching, Zbigniew Nowecki, Javier Pascual, Shin-Cheh Chen, Lionel Moreau, Manuel Ruiz-Borrego, Ayelet Shai, Nuri Karadurmus, Kyung Hae Jung, Yuichiro Kikawa, Richard D Baird, Ranya Habash, Rebecca Sugarman, Steven Fox, Manuel Selvi Miralles, Cynthia Huang Bartlett, Nicholas Turner · 2026

Read SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy by Adam Brufsky, Yeon Hee Park, François-Clément Bidard, Erica L Mayer, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Hiroji Iwata, Peter A Fasching, Zbigniew Nowecki, Javier Pascual, Shin-Cheh Chen, Lionel Moreau, Manuel Ruiz-Borrego, Ayelet Shai, Nuri Karadurmus, Kyung Hae Jung, Yuichiro Kikawa, Richard D Baird, Ranya Habash, Rebecca Sugarman, Steven Fox, Manuel Selvi Miralles, Cynthia Huang Bartlett, Nicholas Turner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13471996.txt.

Description

Brufsky and colleagues reported eye-related results from the SERENA-6 trial in 2026, testing camizestrant for advanced breast cancer. The trial enrolled 315 patients whose blood tests showed new ESR1 gene changes during first-line hormone-based treatment. Patients were assigned at random to switch to camizestrant plus a CDK4/6 blocker, a drug that slows cell division, or to stay on their first treatment.

Visual side effects were more common with camizestrant, affecting about one in three patients, yet nine in ten cases were mild and none forced anyone to stop treatment. Eye exams found no change in sharpness of vision or in the structure of the eye. Patients said the effects, such as flashes of light, began within two weeks, lasted under a minute, and faded after treatment ended. Daily visual function stayed close to starting levels in both groups, which helps doctors counsel patients on what to expect.

Catalog record

CREATORAdam Brufsky, Yeon Hee Park, François-Clément Bidard, Erica L Mayer, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Hiroji Iwata, Peter A Fasching, Zbigniew Nowecki, Javier Pascual, Shin-Cheh Chen, Lionel Moreau, Manuel Ruiz-Borrego, Ayelet Shai, Nuri Karadurmus, Kyung Hae Jung, Yuichiro Kikawa, Richard D Baird, Ranya Habash, Rebecca Sugarman, Steven Fox, Manuel Selvi Miralles, Cynthia Huang Bartlett, Nicholas Turner
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13471996

Browse the full library · About the Tower of Babel